A Proof of Concept Study of Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant

Trial Profile

A Proof of Concept Study of Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs Elbasvir/grazoprevir (Primary)
  • Indications Hepatitis C
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 01 Feb 2017 Status changed from not yet recruiting to recruiting.
    • 03 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top